Capital Impact Advisors LLC lifted its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 283.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 182,088 shares of the company's stock after acquiring an additional 134,548 shares during the period. Capital Impact Advisors LLC's holdings in Ginkgo Bioworks were worth $242,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently made changes to their positions in DNA. Putnam Investments LLC grew its position in Ginkgo Bioworks by 27.6% during the first quarter. Putnam Investments LLC now owns 3,201,699 shares of the company's stock valued at $4,258,000 after purchasing an additional 693,123 shares in the last quarter. Ameriprise Financial Inc. grew its position in Ginkgo Bioworks by 20.0% in the first quarter. Ameriprise Financial Inc. now owns 110,426 shares of the company's stock worth $147,000 after acquiring an additional 18,425 shares in the last quarter. State Street Corp grew its position in Ginkgo Bioworks by 5.8% in the first quarter. State Street Corp now owns 14,707,508 shares of the company's stock worth $19,560,000 after acquiring an additional 800,982 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Ginkgo Bioworks in the first quarter worth approximately $1,935,000. Finally, Geode Capital Management LLC grew its position in Ginkgo Bioworks by 16.2% in the first quarter. Geode Capital Management LLC now owns 13,686,396 shares of the company's stock worth $18,203,000 after acquiring an additional 1,911,342 shares in the last quarter. 56.84% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Ginkgo Bioworks
In related news, insider Reshma P. Shetty sold 37,650 shares of the firm's stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $2.47, for a total value of $92,995.50. Following the completion of the transaction, the insider now directly owns 13,202,854 shares of the company's stock, valued at $32,611,049.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Mark E. Dmytruk sold 40,637 shares of the business's stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $1.80, for a total value of $73,146.60. Following the completion of the transaction, the insider now owns 461,432 shares of the company's stock, valued at $830,577.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Reshma P. Shetty sold 37,650 shares of the business's stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $2.47, for a total value of $92,995.50. Following the completion of the transaction, the insider now directly owns 13,202,854 shares of the company's stock, valued at approximately $32,611,049.38. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,293,870 shares of company stock valued at $2,608,342. 15.05% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Several analysts have commented on DNA shares. The Goldman Sachs Group downgraded shares of Ginkgo Bioworks from a "neutral" rating to a "sell" rating and decreased their target price for the stock from $3.00 to $1.25 in a research report on Friday, June 2nd. Raymond James decreased their price objective on shares of Ginkgo Bioworks from $5.00 to $3.50 and set an "outperform" rating for the company in a report on Thursday, August 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $3.75.
Read Our Latest Stock Analysis on Ginkgo Bioworks
Ginkgo Bioworks Stock Performance
Shares of DNA stock opened at $2.03 on Thursday. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $1.12 and a 52 week high of $3.52. The company has a market capitalization of $4.25 billion, a P/E ratio of -2.85 and a beta of 1.17. The company's 50 day moving average price is $2.06 and its two-hundred day moving average price is $1.66.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). Ginkgo Bioworks had a negative net margin of 375.48% and a negative return on equity of 66.58%. The company had revenue of $80.57 million for the quarter, compared to the consensus estimate of $70.41 million. Analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -0.35 earnings per share for the current year.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report